We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Biomarker Could Predict Immunotherapy Response in Liver Cancer

By LabMedica International staff writers
Posted on 25 Oct 2024

Until recently, patients diagnosed with hepatocellular carcinoma had limited treatment options, with existing therapies extending life by only a few months. More...

Immunotherapy has emerged as a new alternative for these patients, potentially extending their lives by up to two years. However, not all patients respond to immunotherapy, and only a small fraction achieve long-term remission, making it difficult for clinicians to predict who might benefit. Now, a preclinical study suggests it may soon be possible to identify which patients with hepatocellular carcinoma would respond favorably to immunotherapy.

In this study, investigators at Weill Cornell Medicine (New York, NY, USA) sought to uncover biomarkers and therapeutic targets by investigating the liver’s healing mechanisms and how they can lead to cancer. The study offers fresh insights into two proteins, p62 and NBR1, and their contrasting roles in modulating the interferon response in hepatic stellate cells, which are vital to the liver's immune response against tumors. Previous research indicated that levels of the tumor-suppressing protein p62 are permanently reduced in patients who develop hepatocellular carcinoma. The new findings revealed that p62 typically fosters an immune response by activating a protein known as STING, which displaces the immune-suppressing NBR1, thereby initiating an immune response that targets tumor cells. Conversely, NBR1 facilitates the degradation of STING and inhibits the immune response. Removing NBR1 from hepatic stellate cells in mice with hepatocellular carcinoma restored the immune response and reduced tumor size, even when p62 levels remained low.

Thus, the study findings, published in Molecular Cell, indicated that elevated NBR1 levels in these specialized cells could identify patients who are unlikely to respond to immunotherapy. Additionally, strategies aimed at reducing NBR1 levels were shown to diminish tumors in animal models, indicating a potential new treatment approach for patients who do not respond to immunotherapy. The research team is now exploring the development of a therapy that would degrade NBR1 in patients, preventing it from interacting with STING. Their objective is to reactivate the immune system and enhance the efficacy of immunotherapy. Drugs that activate STING are also being developed and may offer another strategy to boost the immune response in patients with hepatocellular carcinoma. Furthermore, the team plans to investigate whether reducing NBR1 could help prevent the metastasis of various cancer types or stop tumors from becoming resistant to treatment. They intend to continue their exploration of the pathways that regulate the liver's immune response.

“If we don’t fully comprehend the molecular mechanisms regulating these processes, immunotherapy will not progress, and we won't be able to understand why it works in some patients and not others,” said co-principal investigator Dr. Maria Diaz-Meco, the Homer T. Hirst Professor of Oncology in Pathology and a member of the Meyer Cancer Center at Weill Cornell Medicine.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.